A fever is one of the most common signs of illness in children. In most cases where febrile episodes are repeated frequently or prolonged beyond two to three weeks, specific infections, malignancies, or autoimmune rheumatic diseases are the main cause of the condition. Systemic juvenile idiopathic arthritis (sJIA) is one such febrile disease in children, and is characterized by systemic inflammatory features such as a spiking fever, skin rash, serositis, and hepatosplenomegaly, in addition to persistent arthritis 1) . According to two nation-wide surveys conducted in Japan, sJIA is the major subtype of JIA; with 42-54% of JIA patients being diagnosed with sJIA, and the number of sJIA patients is estimated to be more than 1,000 [2] [3] . Therefore, sJIA is the most common disease among pediatric rheumatologists in Japan. Although the clinical features resemble to many infectious diseases, sJIA has not been consistently associated with any pathogen. In addition, no auto-antibodies or auto-reactive T cells are detected in patients with sJIA. Furthermore, genetic associations with human leukocyte antigen (HLA) class I or II alleles have not been identified at present. On the other hand, a large amount of evidences of cells and cytokines of innate immune response have been accumulating in sJIA. Based on these recent data, a new consensus is now emerging that sJIA may be an autoinflammatory disease 4) .
Table1: Comparison between autoimmunity and innate immunity

Autoinflammatory Diseases
The autoinflammatory diseases are a group of recently recognized diseases characterized by systemic inflammation mediated by the cells and molecules of the innate immune system, with a significant host predilection 5) . Patients with this disease exhibit repeated or prolonged febrile episodes affecting the skin, joints, the gastrointestinal tract, or serous membranes, without signs of infection or autoimmune phenomena. These inflammatory symptoms are caused by aberrant sensor activation or failure of the inhibitory mechanism of the innate immune response. Therefore, monocytes, macrophages, granulocytes, or natural killer (NK) cells are the pathogenic cells in autoinflammatory disease, in contrast to autoimmune diseases in which T cells and B cells play the major pathogenic role ( Table 1) .
The term 'systemic autoinflammatory syndrome' was first used by Kastner et al in 1999 in the report about TNF receptor-associated periodic syndrome (TRAPS) 5) . Thereafter, the spectrum of the autoinflammatory diseases has been spreading; it now includes periodic fever syndromes (hereditary or non-hereditary), some chronic granulomatous diseases, vascular diseases, and metabolic diseases. In addition, some rheumatic diseases with sero-negative features such as Behcet disease and sJIA are now being considered as autoinflammatory diseases ( Table 2 ). The clinical features of these autoinflammatory diseases are summarized in Tables 3a-d. JIA is defined as arthritis in one or more joints persisting for 6 weeks or longer, which begins before the 16th birthday and has no other known cause 1) . It includes 6 subtypes of diseases including sJIA. The incidence of sJIA patients in all JIA was 42% in Japanese subjects in a nation-wide survey 2) . This is a relatively high incidence rate compared with that of the US or European countries (usually < 10%). In addition, the peak age of onset in sJIA patient is 2-4 years, which is the youngest among patients with other subtypes of JIA. These findings may indicate that there is a genetic background responsible for the pathogenesis of sJIA. Systemic JIA as an Autoinflammatory Disease The clinical features of sJIA are similar to those seen in patients with autoinflammatory diseases 6) . In the active phase of sJIA, the patient's body temperature suddenly rises to 39°C or higher, and is accompanied by severe malaise and tachycardia, with a rapid return to baseline or below the baseline (spiking fever) on a daily or twice-daily basis (quotidian pattern). The intermittent fever persists for at least 2 weeks, and is almost always accompanied by a non-fixed evanescent erythematous rash that has been described as being salmon pink in color. Some patients in the active phase develop systemic serositis such as pericarditis, pleuritis, or pan-peritonitis. Hepatosplenomegaly or systemic lymphadenitis is frequently observed. About 8% of sJIA patients develop macrophage activating syndrome (MAS) which is also recognized to be an autoinflammatory disease.
2) Disease course in sJIA
The systemic inflammation in sJIA is essentially self-limited. The acute manifestations, such as fever or rash, tend to subside during the initial months to years of the disease. Studies over the last 30 years have consistently shown that about half of the children with sJIA have attained drug-free remission after a variable period [7] [8] [9] [10] . According to our follow-up data of 50 sJIA patients observed for a mean 7.9 years, 32% of the sJIA children followed a monocyclic disease course and eventually recovered after a variable period. In the follow-up study, 24% of children had a polycyclic course characterized by recurrent episodes of active disease interrupted by periods of remission without treatment. The disease course of sJIA is compatible with that of some autoinflammatory diseases. For example, the cyclic episodes ceased after a mean of 5.4 years from the onset in patients with periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) and; approximately one third of patients stopped having episodes, and the symptoms became less intense and less frequent with the passage of time in the rest of the patients [11] [12] . Due to the clinical symptoms and the disease course, a number of children with other autoinflammatory diseases might be misdiagnosed as having sJIA. In fact, 9 of 13 patients diagnosed as having an autoinflammatory disease by gene examination in the past 5 years in our clinic were initially diagnosed with sJIA (Table 4) . Two cases of tumor necrosis factor receptor-associated periodic syndrome (TRAPS), shown in Table 4 , were siblings, which provide a clue that helped us make a proper diagnosis 13) . Systemic JIA as an Autoinflammatory Disease The Pathophysiological Course of sJIA is Similar to Autoinflammatory Diseases
1) Prominent innate immunity in sJIA
Several studies have indicated that the role of the adaptive immune system in sJIA may be rather limited compared with the other JIA subtypes, while the contribution of the innate immune system may be much more prominent [14] [15] [16] [17] [18] [19] .
Several studies using the microarray technology that allows for simultaneous assessment of the expression of thousands of genes have shown that sJIA is distinguished from other subtypes of JIA by the up-regulation of innate immune pathways, including IL-6, TLR/IL1R, and the peroxisome proliferator-activated receptor (PPAR) signaling pathways associated with down-regulation of the gene networks involving natural killer (NK)-T cell and major histocompatibility complex (MHC) antigen-related biological process, including antigen presentation 14, [16] [17] [18] [19] [20] .
2) Major effector cells in sJIA
The main pathogenic cells in sJIA are neutrophils, macrophages, monocytes, and NK cells, which are all closely involved in the innate immune response.
In the active phase of sJIA, an increased number of neutrophils and monocytes associated with the expansion of immature myelomonocytoid precursors of CD34+cells or CD33+cells are often seen 16) . In addition, extremely high levels of S100 proteins derived from activated neutrophils and monocytes are reported in both patients with sJIA and those with familial Mediterranean fever (FMF), which is the most common Mendelian autoinflammatory disease that is characterized by autosomal recessive mutations in the MEFV locus [21] [22] .
Macrophage activation syndrome (MAS) is the most devastating condition related to sJIA, and is associated with serious morbid-ity and sometimes death. It occurs in at least 7% of sJIA patients during the disease course, but rarely occurs in patients with other subtypes of JIA 23) . MAS most often occurs during the active phase of sJIA, but has been reported to occur at the time of disease onset [24] [25] .
3) Pivotal cytokines involved in sJIA
Potent pro-inflammatory cytokines, including IL-1, IL-6, and IL-18, have been reported to be pivotal cytokines in the inflammatory process of both autoinflammtory diseases and sJIA. The inflammatory process observed in some autoinflammtory diseases is explained by the formation of an abnormal inflammasome complex that eventually activates the caspase 1 pathway, which resulted in excessive IL-1β and IL-18 production.
In the pathogenesis of sJIA, an important role for IL-1 was first reported by Pascual et al 14) . They showed that the serum from sJIA patients induced the transcription of various innate immunity genes, including IL-1beta, in peripheral blood mononuclear cells obtained from healthy individuals.
High levels of serum IL-18 were also reported in sJIA patients not only in the active phase, but also in the convalescent phase of the disease [26] [27] . In addition, the high levels of IL-18 were derived from CD 68+ macrophages in the bone marrow 26) .
On the other hand, high levels of IL-6 in serum or synovial fluids in patients with sJIA was described beginning in the 1990s, and the level of IL-6 correlates well with the overall clinical activity of the disease. These findings provide a rationale for the use of biological blocking agents for IL-1 and IL-6. A clinical trial for sJIA patients was first conducted in Japan using an anti-IL-6 receptor antibody, tocilizumab (TCZ). The results were completely successful in terms of its efficacy and safety 28) , and the Japanese Ministry of Health, Labor and Welfare ap-Systemic JIA as an Autoinflammatory Disease proved its use in children with refractory sJIA in 2008.
In 2008, the FDA also approved rilonacept, an IL-1 blocking agents, for patients with cryopyrin-associated periodic syndrome (CAPS) which is an autoinflammatory disease. The IL-1 blockers are now recognized as an effective biologics in both patients with autoinflammatory diseases and sJIA [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] (Table 5).
Conclusions
It is clear that the pathogenesis of sJIA is closely associated with abnormalities in the innate immune system, rather than with classic auto-immunity. Patients with sJIA should therefore be viewed as having a pathophysiological condition similar to that observed in autoinflammatory diseases. Further studies on the genetics and molecular pathophysiology are essential in order to deepen our understanding of human innate immunity, and to offer more targeted therapies for patients with sJIA. 
